Protein Kinase D inhibitor CRT0066101 Small Molecule (Tool Compound)

The Protein Kinase D inhibitor CRT0066101 is a potent antitumoral agent in vitro and in vivo.

Contributors

Inventor Institute
Mark Charles Cancer Research Technology
Cat. #: 151831
Tool sub type: Inhibitor
Research Fields: Cancer;Cell signaling and signal transduction;Genetics
Application: In Panc-1 subcutaneous xenograft model, orally administration of CRT0066101 at the dosage of 80 mg/kg/d for 24 days significantly suppressed pancreatic cancer growth. Moreover, when CRT0066101 reached its peak concentration (12 Îźmol/L) in tumor model, the expression of activated PKD1/2 in the treated tumor explants was substantially decreased. It was concluded that CRT0066101 given orally at 80 mg/kg/d for 21 days in Panc-1 orthotropic model suppressed tumor growth potently in vivo. Clinical…
Purpose: Inhibitor
Product description: The Protein Kinase D inhibitor CRT0066101 is a potent antitumoral agent in vitro and in vivo. Protein kinase D (PKD) is an evolutionarily conserved protein kinase family with structural, enzymological, and regulatory properties different from the PKC family members. Signaling through PKD is induced by a remarkable number of stimuli, including G-protein-coupled receptor agonists and polypeptide growth factors. PKD1, the most studied member of the family, is increasingly implicated in the regulation of a complex array of fundamental biological processes, including signal transduction, cell proliferation and differentiation, membrane trafficking, secretion, immune regulation, cardiac hypertrophy and contraction, angiogenesis, and cancer. PKD mediates such a diverse array of normal and abnormal biological functions via dynamic changes in its spatial and temporal localization, combined with its distinct substrate specificity. Studies on PKD thus far indicate a striking diversity of both its signal generation and distribution and its potential for complex regulatory interactions with multiple downstream pathways, often regulating the subcellular localization of its targets.
Additional notes: Using Panc-1 as a model system, it has been demonstrated that CRT0066101: • Reduced bromodeoxyuridine incorporation • Increased apoptosis • Blocked neurotensin-induced PKD1/2 activation • Reduced neurotensin-induced, PKD-mediated Hsp27 phosphorylation • Attenuated PKD1-mediated NF-κB activation • Abrogated the expression of NF-κB-dependent proliferative and pro-survival proteins Molecular Weight: 374.86776 (HCl salt) 338.40712 (free base) g/mol
Molecular weight: 374.86776
Selectivity: Selectivity for PKD against a panel of >90 protein kinases, including PKCÎą, MEK, ERK, c-Raf and c-Src.
Primary target: Protein Kinase D (PKD)
Shipping conditions: Dry Ice
References:

Harikumar et al. 2010. Mol Cancer Ther. 9:1136-1146.PMID: 20442301 Ochi et al. 2011. Journal of Cellular Physiology. 226: 1074-1081. PMID: 20857418 Yuang et al. 2012. Frontiers in Physiology. 3:60. PMID: 22470346 Yang et al. 2013. PNAS (vol 10:6-2312-17). PMID: 23345428 Berhnart et al. 2013. Experimental Cell Research (vol319)-2037-2048. PMID: 23562655 Wei et al. 2014. Molecular Cancer Therapeutics. PMID: 24634417 Ryvkin et al. 2015. J Biol Chem. 290(17):11199-208. PMID: 25802335.

Related Tools for Small molecules

Cat. # Tool Name
151839 Antitumoral Phortress Small Molecule (Tool Compound) Key Info View Tool
152741 Platinum trimethyl Luminophore Small Molecule (Tool Compound) Key Info View Tool
152754 CDK2 inhibitor NU6301 Small Molecule (Tool Compound) Key Info View Tool
152785 Mitochondrial Luminophore Small Molecule (Tool Compound) Key Info View Tool
153255 Autotaxin Inhibitor (CRT0273750) Small Molecule (Collaborative Toolkit) Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.